Hortobagyi GN - Search Results

1

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer.

Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Liedtke C, et al. Among authors: hortobagyi gn. J Clin Oncol. 2023 Apr 1;41(10):1809-1815. doi: 10.1200/JCO.22.02572. J Clin Oncol. 2023. PMID: 36989609

2

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al. Buzdar AU, et al. Among authors: hortobagyi gn. J Clin Oncol. 1992 Oct;10(10):1540-6. doi: 10.1200/JCO.1992.10.10.1540. J Clin Oncol. 1992. PMID: 1403033 Clinical Trial.

3

Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy.

Fraschini G, Ciociola A, Esparza L, Templeton D, Holmes FA, Walters RS, Hortobagyi GN. Fraschini G, et al. Among authors: hortobagyi gn. J Clin Oncol. 1991 Jul;9(7):1268-74. doi: 10.1200/JCO.1991.9.7.1268. J Clin Oncol. 1991. PMID: 1828499 Clinical Trial.

4

Measurement of estrogen and progesterone receptors in human breast tumors: enzyme immunoassay versus binding assay.

Holmes FA, Fritsche HA, Loewy JW, Geitner AM, Sutton RC, Buzdar AU, Hortobagyi GN. Holmes FA, et al. Among authors: hortobagyi gn. J Clin Oncol. 1990 Jun;8(6):1025-35. doi: 10.1200/JCO.1990.8.6.1025. J Clin Oncol. 1990. PMID: 2189952

5

Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support.

Dunphy FR, Spitzer G, Buzdar AU, Hortobagyi GN, Horwitz LJ, Yau JC, Spinolo JA, Jagannath S, Holmes F, Wallerstein RO, et al. Dunphy FR, et al. Among authors: hortobagyi gn. J Clin Oncol. 1990 Jul;8(7):1207-16. doi: 10.1200/JCO.1990.8.7.1207. J Clin Oncol. 1990. PMID: 2358837 Clinical Trial.

6

A comparative study of doxorubicin and epirubicin in patients with metastatic breast cancer.

Hortobagyi GN, Yap HY, Kau SW, Fraschini G, Ewer MS, Chawla SP, Benjamin RS. Hortobagyi GN, et al. Am J Clin Oncol. 1989 Feb;12(1):57-62. doi: 10.1097/00000421-198902000-00014. Am J Clin Oncol. 1989. PMID: 2643296 Clinical Trial.

7

Ten-year results of FAC adjuvant chemotherapy trial in breast cancer.

Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Buzdar AU, et al. Among authors: hortobagyi gn. Am J Clin Oncol. 1989 Apr;12(2):123-8. doi: 10.1097/00000421-198904000-00007. Am J Clin Oncol. 1989. PMID: 2705401

8

Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma.

Ang PT, Buzdar AU, Smith TL, Kau S, Hortobagyi GN. Ang PT, et al. Among authors: hortobagyi gn. J Clin Oncol. 1989 Nov;7(11):1677-84. doi: 10.1200/JCO.1989.7.11.1677. J Clin Oncol. 1989. PMID: 2809682

9

Management of locally advanced breast cancer.

Hortobagyi GN, Buzdar AU. Hortobagyi GN, et al. Am J Clin Oncol. 1988 Oct;11(5):597-601. doi: 10.1097/00000421-198810000-00018. Am J Clin Oncol. 1988. PMID: 2845771 No abstract available.

10

Bilateral primary breast cancer in patients treated with adjuvant therapy.

Berté E, Buzdar AU, Smith TL, Hortobagyi GN. Berté E, et al. Among authors: hortobagyi gn. Am J Clin Oncol. 1988 Apr;11(2):114-8. doi: 10.1097/00000421-198804000-00005. Am J Clin Oncol. 1988. PMID: 3128945 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,108 results

Search Page

Filters